These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37023729)

  • 21. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
    Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
    JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
    Shi Y; Wu J; Wang Z; Zhang L; Wang Z; Zhang M; Cen H; Peng Z; Li Y; Fan L; Guo Y; Ma L; Cui J; Gao Y; Yang H; Zhang H; Wang L; Zhang W; Zhang H; Xie L; Jiang M; Zhou H; Shuang Y; Su H; Ke X; Jin C; Du X; Du X; Liu L; Xi Y; Ge Z; Feng R; Zhang Y; Zhou S; Xie F; Wang Q
    J Hematol Oncol; 2021 Jan; 14(1):12. PubMed ID: 33436023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.
    Lin N; Zhang M; Bai H; Liu H; Cui J; Ke X; Zhang H; Liu L; Yan D; Jiang Y; Zang A; Qi J; Wang L; Liu Z; Xu B; Zhang Y; Zhang Z; Zhao X; Hu C; Yang S; Zhou H; Shi J; Shao Z; Xiang Y; Zhu J; Song Y; Zhu J
    Eur J Cancer; 2022 Mar; 164():117-126. PubMed ID: 34462189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
    Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.
    Fedorova LV; Lepik KV; Mikhailova NB; Kondakova EV; Zalyalov YR; Baykov VV; Babenko EV; Kozlov AV; Moiseev IS; Afanasyev BV
    Ann Hematol; 2021 Mar; 100(3):691-698. PubMed ID: 33528609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
    Gillessen S; Pluetschow A; Vucinic V; Ostermann H; Kobe C; Bröckelmann PJ; Böll B; Eichenauer DA; Heger JM; Borchmann S; Fuchs M; Borchmann P; Engert A; von Tresckow B
    Eur J Haematol; 2022 Dec; 109(6):728-735. PubMed ID: 36056778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
    Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Thiruvengadam SK; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):523-530. PubMed ID: 38714474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
    Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
    Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tislelizumab for the treatment of classical Hodgkin's lymphoma.
    Chen J; Zhang H; Zhu L; Zhao Y; Ding Y; Yuan Y
    Drugs Today (Barc); 2020 Dec; 56(12):781-785. PubMed ID: 33332484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Beköz H; Karadurmuş N; Paydaş S; Türker A; Toptaş T; Fıratlı Tuğlular T; Sönmez M; Gülbaş Z; Tekgündüz E; Kaya AH; Özbalak M; Taştemir N; Kaynar L; Yıldırım R; Karadoğan I; Arat M; Pepedil Tanrıkulu F; Özkocaman V; Abalı H; Turgut M; Kurt Yüksel M; Özcan M; Doğu MH; Kabukçu Hacıoğlu S; Barışta I; Demirkaya M; Köseoğlu FD; Toprak SK; Yılmaz M; Demirkürek HC; Demirkol O; Ferhanoğlu B
    Ann Oncol; 2017 Oct; 28(10):2496-2502. PubMed ID: 28961828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
    Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
    Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
    Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Zhao X; Wang D; Zhang P; Wang Y; Wang L; Liu T; Zhang Y; Shen Z; Huang J; Zhu J
    Clin Cancer Res; 2022 Mar; 28(6):1147-1156. PubMed ID: 34716199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study.
    Sun P; Yang H; Wang Y; Zhao B; Nie M; Huang K; Li Z
    Ann Hematol; 2024 Mar; 103(3):793-801. PubMed ID: 37953379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
    Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
    Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
    Xu B; Li S; Kang B; Fan S; He Z; Zhou J
    Invest New Drugs; 2022 Dec; 40(6):1333-1341. PubMed ID: 36074313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
    EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.